Pluri (PLUR) Return on Capital Employed (2011 - 2025)
Pluri (PLUR) reported Return on Capital Employed of 11734.43% for Q4 2025, up 1181009.0% year-over-year from N/an in Q4 2024, and up 2120.88% quarter-over-quarter from 580.66% in Q3 2025.
Pluri (PLUR) Return on Capital Employed (2011 - 2025) Analysis & Trends
Pluri (PLUR) has 15 years of Return on Capital Employed data on file, last reported at 11734.43% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 11734.43%, up 1181009.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 11734.43% (up 1181009.0% YoY), and the FY2025 annual result was 327.22%, down 27279.0% from the prior year.
- Return on Capital Employed advanced to 11734.43% in Q4 2025 per PLUR's latest filing, from 580.66% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11734.43% in Q4 2025 and troughed at 580.66% in Q3 2025.
- A 5-year average of 482.18% and a median of 65.97% in 2024 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 1181009 bps in 2025 and fell as far as 51386 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 70.05% in 2021, then rose by 14 bps to 60.41% in 2022, then decreased by 4 bps to 62.91% in 2023, then slipped by 20 bps to 75.66% in 2024, then surged by 15610 bps to 11734.43% in 2025.
- Business Quant data shows PLUR's Return on Capital Employed at 11734.43% in Q4 2025, 580.66% in Q3 2025, and 387.9% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | 11,734.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11,734.43% |
| Sep 30, 2025 | -580.66% |
| Jun 30, 2025 | -387.90% |
| Mar 31, 2025 | -75.94% |
| Dec 31, 2024 | -75.66% |
| Sep 30, 2024 | -66.80% |
| Jun 30, 2024 | -66.13% |
| Mar 31, 2024 | -65.80% |
| Dec 31, 2023 | -62.91% |
| Sep 30, 2023 | -59.29% |
| Jun 30, 2023 | -56.88% |
| Mar 31, 2023 | -56.13% |
| Dec 31, 2022 | -60.41% |
| Sep 30, 2022 | -62.95% |
| Jun 30, 2022 | -62.30% |
| Mar 31, 2022 | -65.39% |
| Dec 31, 2021 | -70.05% |
| Sep 30, 2021 | -68.13% |
| Jun 30, 2021 | -67.64% |
| Mar 31, 2021 | -79.84% |